{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:03:43Z","timestamp":1770483823310,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1595,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1365-2036.2011.04656.x","type":"journal-article","created":{"date-parts":[[2011,4,21]],"date-time":"2011-04-21T01:51:54Z","timestamp":1303350714000},"page":"1311-1321","source":"Crossref","is-referenced-by-count":28,"title":["Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome"],"prefix":"10.1111","volume":"33","author":[{"given":"S.","family":"Zakko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dunger-Baldauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"R\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,20]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MEG.0b013e32801140e2","article-title":"A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the \u2018true\u2019 prevalence of irritable bowel syndrome?","volume":"19","author":"Sperber","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s10620-006-3153-8","article-title":"Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a population-based study","volume":"51","author":"Minocha","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB4|cit4","first-page":"1910","article-title":"The epidemiology of irritable bowel syndrome in North America: a systematic review","volume":"97","author":"Saito","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB5|cit5","first-page":"24","article-title":"Quality of life in managed care patients with irritable bowel syndrome","volume":"17","author":"Wilson","year":"2004","journal-title":"Manag Care Interface"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB7|cit7","volume-title":"Rome II: The Functional Gastrointestinal Disorders","author":"Drossman","year":"2000"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB8|cit8","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2006.03.008","volume-title":"Rome III. The Functional Gastrointestinal Disorders","author":"Drossman","year":"2006"},{"issue":"Suppl 2","key":"10.1111\/j.1365-2036.2011.04656.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"II43","DOI":"10.1136\/gut.45.2008.ii43","article-title":"Functional bowel disorders and functional abdominal pain","volume":"45","author":"Thompson","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1572-0241.2006.00404.x","article-title":"Abdominal pain impacts quality of life in women with irritable bowel syndrome","volume":"101","author":"Cain","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/j.1572-0241.2002.07111.x","article-title":"Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome","volume":"97","author":"Olden","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data","volume":"101","author":"Chang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5\u2003mg and 1\u2003mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1053\/gast.1997.v112.agast972120","article-title":"Irritable bowel syndrome: a technical review for practice guideline development","volume":"112","author":"Drossman","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2982.2002.00332.x","article-title":"Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome","volume":"14","author":"Steens","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000094099","article-title":"Relationship of underlying abnormalities in rectal sensitivity and compliance to distension with symptoms in irritable bowel syndrome","volume":"73","author":"Lee","year":"2006","journal-title":"Digestion"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1572-0241.2006.00672.x","article-title":"Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes","volume":"101","author":"Dunlop","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00042737-200602000-00007","article-title":"Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups","volume":"18","author":"Zar","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bjp.0704217","article-title":"A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine","volume":"134","author":"Lordal","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/sj.bjp.0705751","article-title":"Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome","volume":"141","author":"Lecci","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0016-5085(99)70015-6","article-title":"Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies","volume":"116","author":"Julia","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-3565(24)29307-1","article-title":"Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia","volume":"299","author":"Kamp","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3748\/wjg.v11.i2.237","article-title":"Increase in neurokinin-1 receptor-mediated colonic motor response in a rat model of irritable bowel syndrome","volume":"11","author":"La","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/gut.2007.126680","article-title":"Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats","volume":"57","author":"Barreau","year":"2008","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/S0960-894X(01)00631-X","article-title":"Dual neurokinin NK(1)\/NK(2) antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3, 5-bis(trifluoromethyl)benzamides and 3-[N\u2019-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N\u2019-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides","volume":"11","author":"Gerspacher","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB27|cit27","first-page":"A627","article-title":"Effects of DNK333, a dual NK1\/NK2 neurokinin receptor antagonist, on airway responsiveness induced by lipopolysaccharide or allergen challenge in the guinea-pig","volume":"163","author":"Fozard","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00210-002-0671-6","article-title":"Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa","volume":"367","author":"Tough","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0016-5085(91)90275-P","article-title":"Irritable bowel syndrome in office-based practice in the United States","volume":"100","author":"Everhart","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2036.1997.84256000.x","article-title":"Review article: irritable bowel syndrome","volume":"11","author":"Camilleri","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/bmj.300.6722.439","article-title":"Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate","volume":"300","author":"O\u2019Donnell","year":"1990","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.2517-6161.1951.tb00088.x","article-title":"The interpretation of interaction in contingency tables","volume":"13","author":"Simpson","year":"1951","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2125.2003.01966.x","article-title":"Evaluation of drug treatment in irritable bowel syndrome","volume":"56","author":"Talley","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04656.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1183\/09031936.03.00101902","article-title":"Dual tachykinin NK1\/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients","volume":"23","author":"Joos","year":"2004","journal-title":"Eur Respir J"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04656.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04656.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:27:49Z","timestamp":1741152469000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04656.x"}},"subtitle":["Randomised clinical trial: DNK333, a neurokinin antagonist, in IBS-D"],"short-title":[],"issued":{"date-parts":[[2011,4,20]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04656.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,20]]}}}